Pfizer Company Insiders
PFE Stock | USD 29.22 0.05 0.17% |
About 59% of Pfizer's corporate insiders are selling. The analysis of insiders' sentiment of trading Pfizer Inc stock suggests that many insiders are alarmed at this time. Pfizer employs about 88 K people. The company is managed by 41 executives with a total tenure of roughly 235 years, averaging almost 5.0 years of service per executive, having 2146.34 employees per reported executive.
John Young President Group President - Pfizer Innovative Health and Angela Hwang |
Frank DAmelio President Chief Financial Officer, Executive Vice President - Business Operations and Global Supply |
Pfizer's Insider Buying Vs Selling
41
Selling | Buying |
Latest Trades
2024-08-09 | Kathy E. Manning | Disposed @ 28.55 | |||
2024-08-06 | C. Scott Franklin | Disposed @ 29.3 | |||
2024-08-01 | C. Scott Franklin | Disposed @ 30.65 | |||
2024-05-03 | Tommy Tuberville | Disposed @ 27.81 | |||
2024-03-04 | Roger Williams | Disposed @ 25.89 | |||
2024-03-01 | Roger Williams | Acquired @ 26.58 | |||
2024-02-27 | Tommy Tuberville | Acquired @ 26.89 | |||
2024-02-12 | Earl Blumenauer | Acquired @ 27.67 | |||
2023-12-28 | Jared Moskowitz | Disposed @ 28.79 | |||
2023-12-20 | John Boozman | Acquired @ 27.63 | |||
2023-12-18 | Shelley Moore Capito | Disposed @ 27.05 | |||
2023-12-15 | Scott Gottlieb | Acquired 3000 @ 26.47 | View |
Monitoring Pfizer's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Pfizer's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Pfizer Inc. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Pfizer's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Pfizer |
Pfizer's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Pfizer's future performance. Based on our forecasts, it is anticipated that Pfizer will maintain a workforce of about 90000 employees by November 2024.Pfizer's latest congressional trading
Congressional trading in companies like Pfizer Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Pfizer by those in governmental positions are based on the same information available to the general public.
2024-09-04 | Representative Kathy Manning | Acquired Under $15K | Verify | ||
2024-08-21 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
2024-08-20 | Representative C Scott Franklin | Acquired $15K to $50K | Verify | ||
2024-06-14 | Senator Tommy Tuberville | Acquired $15K to $50K | Verify | ||
2024-06-13 | Senator Tommy Tuberville | Acquired $15K to $50K | Verify | ||
2024-06-12 | Representative Roger Williams | Acquired Under $15K | Verify | ||
2024-04-05 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
2024-03-15 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
2024-03-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
2024-03-02 | Representative Earl Blumenauer | Acquired Under $15K | Verify | ||
2024-01-18 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
2024-01-17 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
2024-01-16 | Senator Jerry Moran | Acquired Under $15K | Verify | ||
2024-01-12 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
2024-01-11 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
2024-01-08 | Senator John Boozman | Acquired Under $15K | Verify | ||
2024-01-07 | Senator John Boozman | Acquired Under $15K | Verify | ||
2023-07-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
2023-04-17 | Representative Carol Devine Miller | Acquired Under $15K | Verify | ||
2023-02-24 | Representative Michael Patrick Guest | Acquired Under $15K | Verify | ||
2022-04-06 | Representative Lois Frankel | Acquired Under $15K | Verify | ||
2022-02-27 | Representative Lois Frankel | Acquired Under $15K | Verify | ||
2021-11-03 | Representative Zoe Lofgren | Acquired Under $15K | Verify | ||
2021-06-09 | Representative Earl Blumenauer | Acquired Under $15K | Verify | ||
2021-05-16 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
2020-11-22 | Representative Bob Gibbs | Acquired Under $15K | Verify | ||
2020-09-04 | Representative K Michael Conaway | Acquired $15K to $50K | Verify | ||
2020-08-04 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
2020-08-03 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
2020-07-11 | Representative Mo Brooks | Acquired Under $15K | Verify | ||
2020-03-24 | Representative Mo Brooks | Acquired Under $15K | Verify | ||
2020-02-24 | Representative Lois Frankel | Acquired Under $15K | Verify | ||
2019-02-07 | Representative Robert J Wittman | Acquired Under $15K | Verify | ||
2018-12-06 | Senator David Perdue | Acquired Under $15K | Verify | ||
2016-12-07 | Senator John Hoeven | Acquired $50K to $100K | Verify |
Pfizer Management Team Effectiveness
As of October 19, 2024, Return On Tangible Assets is expected to decline to 0.02. In addition to that, Return On Capital Employed is expected to decline to 0.02. At present, Pfizer's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.7 B, whereas Total Current Assets are forecasted to decline to about 32.2 B. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.The current year's Common Stock Shares Outstanding is expected to grow to about 5.7 B. The current year's Net Income Applicable To Common Shares is expected to grow to about 37.9 B
Pfizer Workforce Comparison
Pfizer Inc is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 198,029. Pfizer totals roughly 88,000 in number of employees claiming about 44% of equities under Health Care industry.
Pfizer Profit Margins
The company has Net Profit Margin of (0.05) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of 0.22 %, which entails that for every 100 dollars of revenue, it generated $0.22 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.62 | 0.5006 |
|
| |||||
Net Profit Margin | 0.0344 | 0.0362 |
|
| |||||
Operating Profit Margin | 0.0688 | 0.0724 |
|
| |||||
Pretax Profit Margin | 0.0172 | 0.0181 |
|
| |||||
Return On Assets | 0.0089 | 0.0094 |
|
| |||||
Return On Equity | 0.0226 | 0.0238 |
|
|
Pfizer Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pfizer insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pfizer's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pfizer insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 1.84 | 46 | 25 | 2,029,407 | 2,046,647 |
2024-06-01 | 16.0 | 32 | 2 | 102,447 | 12,107 |
2024-03-01 | 1.2045 | 53 | 44 | 4,240,517 | 854,465 |
2023-09-01 | 25.0 | 25 | 1 | 6,026 | 0.00 |
2023-06-01 | 39.0 | 39 | 1 | 100,638 | 16,223 |
2023-03-01 | 1.0 | 57 | 57 | 2,792,894 | 1,048,653 |
2022-12-01 | 10.3333 | 31 | 3 | 407,055 | 368,604 |
2022-06-01 | 7.125 | 57 | 8 | 373,722 | 117,822 |
2022-03-01 | 0.9143 | 64 | 70 | 3,135,600 | 1,833,982 |
2021-12-01 | 0.6324 | 43 | 68 | 419,133 | 1,264,052 |
2021-09-01 | 8.5 | 34 | 4 | 48,193 | 4,161 |
2021-06-01 | 14.6667 | 44 | 3 | 65,772 | 16,080 |
2021-03-01 | 0.8933 | 67 | 75 | 4,637,604 | 2,656,850 |
2020-12-01 | 8.75 | 35 | 4 | 23,582 | 187,438 |
2020-06-01 | 2.8421 | 54 | 19 | 78,317 | 208,381 |
2020-03-01 | 0.9663 | 86 | 89 | 5,142,206 | 2,546,317 |
2019-12-01 | 7.0 | 35 | 5 | 6,301 | 12,048 |
2019-09-01 | 2.05 | 41 | 20 | 135,265 | 153,184 |
2019-06-01 | 1.6154 | 42 | 26 | 52,465 | 49,495 |
2019-03-01 | 0.3782 | 104 | 275 | 6,153,830 | 4,978,791 |
2018-12-01 | 8.6 | 43 | 5 | 1,105,760 | 2,247,006 |
2018-09-01 | 0.5625 | 36 | 64 | 204,666 | 1,150,678 |
2018-06-01 | 2.6429 | 37 | 14 | 63,402 | 185,435 |
2018-03-01 | 0.466 | 48 | 103 | 2,406,461 | 2,174,116 |
2017-12-01 | 2.5 | 10 | 4 | 3,234 | 29,450 |
2017-09-01 | 1.1111 | 10 | 9 | 3,282 | 184,543 |
2017-03-01 | 1.0 | 37 | 37 | 1,663,656 | 970,676 |
2016-12-01 | 2.3333 | 21 | 9 | 123,417 | 305,355 |
2016-06-01 | 0.3784 | 28 | 74 | 432,268 | 1,013,128 |
2016-03-01 | 0.9459 | 35 | 37 | 1,637,202 | 994,616 |
2015-12-01 | 17.0 | 17 | 1 | 4,752 | 2,520 |
2015-09-01 | 17.0 | 17 | 1 | 4,759 | 1,000.00 |
2015-06-01 | 3.1111 | 28 | 9 | 105,948 | 104,503 |
2015-03-01 | 0.4536 | 44 | 97 | 1,417,708 | 1,258,003 |
2014-12-01 | 0.9355 | 29 | 31 | 199,816 | 566,489 |
2014-09-01 | 23.0 | 23 | 1 | 8,650 | 1,064 |
2014-06-01 | 5.2 | 26 | 5 | 84,691 | 61,859 |
2014-03-01 | 0.6625 | 53 | 80 | 1,878,990 | 1,541,140 |
2013-12-01 | 2.6471 | 45 | 17 | 144,037 | 243,869 |
2013-09-01 | 5.1 | 51 | 10 | 169,328 | 266,600 |
2013-06-01 | 2.4286 | 51 | 21 | 38,972 | 100,193 |
2013-03-01 | 0.8197 | 50 | 61 | 2,085,489 | 1,401,415 |
2012-12-01 | 5.5 | 33 | 6 | 4,394 | 37,020 |
2012-09-01 | 4.625 | 37 | 8 | 4,692 | 121,517 |
2012-06-01 | 52.0 | 52 | 1 | 53,188 | 19,670 |
2012-03-01 | 3.2143 | 45 | 14 | 2,221,652 | 193,363 |
2011-12-01 | 9.0 | 45 | 5 | 19,412 | 13,403 |
2011-09-01 | 15.0 | 45 | 3 | 10,613 | 35,318 |
2011-06-01 | 25.5 | 51 | 2 | 92,513 | 20,993 |
2011-03-01 | 2.0 | 40 | 20 | 1,616,922 | 99,233 |
2010-12-01 | 1.3929 | 39 | 28 | 8,799 | 811,350 |
2010-09-01 | 18.5 | 37 | 2 | 7,401 | 43,498 |
2010-06-01 | 6.25 | 50 | 8 | 53,762 | 41,614 |
2010-03-01 | 4.6667 | 28 | 6 | 1,827,967 | 203,031 |
2009-12-01 | 10.75 | 43 | 4 | 196,639 | 849.00 |
2009-09-01 | 5.1429 | 36 | 7 | 102,142 | 200,049 |
2009-06-01 | 21.0 | 42 | 2 | 50,384 | 13,600 |
2009-03-01 | 3.2727 | 36 | 11 | 2,303,199 | 505,602 |
2008-09-01 | 50.0 | 50 | 1 | 11,047 | 38,281 |
2008-06-01 | 25.0 | 50 | 2 | 283,066 | 10,000 |
2008-03-01 | 7.6 | 38 | 5 | 1,559,094 | 8,823 |
2007-12-01 | 2.5833 | 31 | 12 | 157,834 | 533,556 |
2007-09-01 | 34.0 | 34 | 1 | 533,595 | 0.00 |
2007-06-01 | 5.125 | 41 | 8 | 161,210 | 104,699 |
2007-03-01 | 2.0667 | 31 | 15 | 1,762,307 | 319,994 |
2006-12-01 | 11.0 | 44 | 4 | 12,115 | 16,146 |
2006-09-01 | 1.56 | 39 | 25 | 858,671 | 1,182,426 |
2006-06-01 | 4.1 | 41 | 10 | 248,777 | 399,464 |
2006-03-01 | 2.9 | 29 | 10 | 2,936,362 | 68,156 |
2005-12-01 | 7.8 | 39 | 5 | 8,765 | 59,925 |
2005-09-01 | 19.5 | 39 | 2 | 357,042 | 655,520 |
2005-06-01 | 6.125 | 49 | 8 | 44,346 | 126,934 |
2005-03-01 | 1.2 | 24 | 20 | 2,336,955 | 1,067,511 |
2004-12-01 | 9.2 | 46 | 5 | 9,714 | 63,616 |
2004-09-01 | 47.0 | 47 | 1 | 26,088 | 17,508 |
2004-06-01 | 21.0 | 63 | 3 | 53,623 | 7,896 |
2004-03-01 | 2.3529 | 40 | 17 | 1,974,456 | 865,954 |
2003-12-01 | 5.2222 | 47 | 9 | 71,159 | 135,061 |
2003-09-01 | 20.5 | 41 | 2 | 25,054 | 19,105 |
Pfizer Notable Stakeholders
A Pfizer stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pfizer often face trade-offs trying to please all of them. Pfizer's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pfizer's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Albert DVM | Chairman CEO | Profile | |
John Young | Group President - Pfizer Innovative Health and Angela Hwang | Profile | |
Frank DAmelio | Chief Financial Officer, Executive Vice President - Business Operations and Global Supply | Profile | |
Douglas Lankler | Executive Vice President General Counsel | Profile | |
Dawn Rogers | Chief Human Resource Officer, Executive Vice President | Profile | |
Mikael Dolsten | Chief Scientific Officer, President - Worldwide Research, Development and Medical | Profile | |
Lidia Fonseca | Executive Vice President, Chief Technology Officer and Digital Officer | Profile | |
Alexander Mackenzie | Executive Vice President Chief Development Officer | Profile | |
Sally Susman | Chief Corporate Affairs Officer, Executive Vice President | Profile | |
Rady Johnson | Chief Compliance, Quality and Risk Officer, Executive Vice President | Profile | |
Albert Bourla | Group President - Vaccines, Oncology and Consumer Healthcare Business | Profile | |
Payal Sahni | Executive Vice President, Chief People Experience Officer | Profile | |
Angela Hwang | Group President - Pfizer Biopharmaceuticals Group | Profile | |
Helen Hobbs | Independent Director | Profile | |
Shantanu Narayen | Lead Independent Director | Profile | |
James Smith | Independent Director | Profile | |
Susan DesmondHellmann | Independent Director | Profile | |
Wyllie Cornwell | Independent Director | Profile | |
Suzanne Johnson | Independent Director | Profile | |
Susan Hockfield | Independent Director | Profile | |
Dan Littman | Independent Director | Profile | |
James Kilts | Independent Director | Profile | |
James Quincey | Independent Director | Profile | |
Joseph Echevarria | Independent Director | Profile | |
Scott Gottlieb | Independent Director | Profile | |
Ronald Blaylock | Independent Director | Profile | |
Payal Becher | Chief VP | Profile | |
Jennifer Damico | Senior Vice President Principal Accounting Officer, Controller | Profile | |
Christopher CFA | VP Officer | Profile | |
Michael Mcdermott | Executive Vice President Chief Global Supply Officer | Profile | |
Francesca DeMartino | Chief Officer | Profile | |
Gordon Loh | Senior Vice President Corporate Audit | Profile | |
David Denton | Chief VP | Profile | |
Aamir Malik | Executive Vice President Chief Business Innovation Officer | Profile | |
Christopher Stevo | Senior Vice President and Chief Investor Relations Officer | Profile | |
DVM DVM | Chairman CEO | Profile | |
William Gray | Independent Director | Profile | |
William Carapezzi | Executive Vice President - Global Business Services and Transformation | Profile | |
Mikael MD | Chief Development | Profile | |
Andreas Panayiotou | Global Officer | Profile | |
Mike Mcdermott | Executive Vice President Chief Global Supply Officer | Profile |
About Pfizer Management Performance
The success or failure of an entity such as Pfizer Inc often depends on how effective the management is. Pfizer management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pfizer management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pfizer management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.02 | 0.02 | |
Return On Capital Employed | 0.02 | 0.02 | |
Return On Assets | 0.01 | 0.01 | |
Return On Equity | 0.02 | 0.02 |
Please note, the presentation of Pfizer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pfizer's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pfizer's management manipulating its earnings.
Pfizer Workforce Analysis
Traditionally, organizations such as Pfizer use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pfizer within its industry.Pfizer Manpower Efficiency
Return on Pfizer Manpower
Revenue Per Employee | 664.7K | |
Revenue Per Executive | 1.4B | |
Net Income Per Employee | 24.2K | |
Net Income Per Executive | 52M |
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |